Reversible Small Molecule Inhibitors of MAO A and MAO B with Anilide Motifs

被引:22
作者
Hagenow, Jens [1 ]
Hagenow, Stefanie [1 ]
Grau, Kathrin [1 ]
Khanfar, Mohammad [1 ,2 ,3 ]
Hefke, Lena [4 ]
Proschak, Ewgenij [4 ]
Stark, Holger [1 ]
机构
[1] Heinrich Heine Univ Dusseldorf, Inst Pharmaceut & Med Chem, Univ Str 1, D-40225 Dusseldorf, Germany
[2] Univ Jordan, Fac Pharm, Amman 11942, Jordan
[3] Alfaisal Univ, Coll Pharm, Riyadh 11533, Saudi Arabia
[4] Goethe Univ Frankfurt, Inst Pharmaceut Chem, D-60438 Frankfurt, Germany
来源
DRUG DESIGN DEVELOPMENT AND THERAPY | 2020年 / 14卷
关键词
salicylic acid derivatives; molecular modeling; Parkinson's disease; enzyme inhibitor; pharmacophore; structure-activity relationships; MONOAMINE-OXIDASE B; ANTIMICROBIAL ACTIVITY; BIOLOGICAL EVALUATION; ANTIMYCOBACTERIAL ACTIVITY; POTENT INHIBITORS; DERIVATIVES; SALICYLANILIDES; ALDEHYDES; DISCOVERY; AMIDES;
D O I
10.2147/DDDT.S236586
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: Ligands consisting of two aryl moieties connected via a short spacer were shown to be potent inhibitors of monoamine oxidases (MAO) A and B, which are known as suitable targets in treatment of neurological diseases. Based on this general blueprint, we synthesized a series of 66 small aromatic amide derivatives as novel MAO A/B inhibitors. Methods: The compounds were synthesized, purified and structurally confirmed by spectroscopic methods. Fluorimetric enzymological assays were performed to determine MAO A/B inhibition properties. Mode and reversibility of inhibition was determined for the most potent MAO B inhibitor. Docking poses and pharmacophore models were generated to confirm the in vitro results. Results: N-(2,4-Dinitrophenyl)benzo [d] [1,3]dioxole-5-carboxamide (55, ST-2043) was found to be a reversible competitive moderately selective MAO B inhibitor (IC50 = 56 nM, K-i = 6.3 nM), while N-(2,4-dinitrophenyl)benzamide (7, ST-2023) showed higher preference for MAO A (IC50 = 126 nM). Computational analysis confirmed in vitro binding properties, where the anilides examined possessed high surface complementarity to MAO A/B active sites. Conclusion: The small molecule anilides with different substitution patterns were identified as potent MAO A/B inhibitors, which were active in nanomolar concentrations ranges. These small and easily accessible molecules are promising motifs, especially for newly designed multitargeted ligands taking advantage of these fragments.
引用
收藏
页码:371 / 393
页数:23
相关论文
共 80 条
  • [1] Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson's disease
    Affini, Anna
    Hagenow, Stefanie
    Zivkovic, Aleksandra
    Marco-Contelles, Jose
    Stark, Holger
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 148 : 487 - 497
  • [2] Synthesis, characterization, monoamine oxidase inhibition, molecular docking and dynamic simulations of novel 2,1-benzothiazine-2,2-dioxide derivatives
    Ahmad, Shakeel
    Zaib, Sumera
    Jalil, Saquib
    Shafiq, Muhammad
    Ahmad, Matloob
    Sultan, Sadia
    Iqbal, Mazhar
    Aslam, Sana
    Iqbal, Jamshed
    [J]. BIOORGANIC CHEMISTRY, 2018, 80 : 498 - 510
  • [3] Niclosamide is a Negative Allosteric Modulator of Group I Metabotropic Glutamate Receptors: Implications for Neuropathic Pain
    Ai, Ni
    Wood, Richard D.
    Yang, Eric
    Welsh, William J.
    [J]. PHARMACEUTICAL RESEARCH, 2016, 33 (12) : 3044 - 3056
  • [4] Bis-picolinamide Ruthenium(III) Dihalide Complexes: Dichloride-to-Diiodide Exchange Generates Single trans Isomers with High Potency and Cancer Cell Selectivity
    Basri, Aida M.
    Lord, Rianne M.
    Allison, Simon J.
    Rodriguez-Barzano, Andrea
    Lucas, Stephanie J.
    Janeway, Felix D.
    Shepherd, Helena J.
    Pask, Christopher M.
    Phillips, Roger M.
    McGowan, Patrick C.
    [J]. CHEMISTRY-A EUROPEAN JOURNAL, 2017, 23 (26) : 6341 - 6356
  • [5] Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: a review of the current clinical evidence
    Bette, Sagari
    Shpiner, Danielle S.
    Singer, Carlos
    Moore, Henry
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2018, 14 : 1737 - 1745
  • [6] Synthesis and biological activity of novel substituted benzanilides as potassium channel activators. V
    Biagi, G
    Giorgi, I
    Livi, O
    Nardi, A
    Calderone, V
    Martelli, A
    Martinotti, E
    Salerni, OL
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2004, 39 (06) : 491 - 498
  • [7] Irreversible Inhibition of Monoamine Oxidase B by the Antiparkinsonian Medicines Rasagiline and Selegiline: A Computational Study
    Borstnar, Rok
    Repic, Matej
    Krzan, Mojca
    Mavri, Janez
    Vianello, Robert
    [J]. EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, 2011, 2011 (32) : 6419 - 6433
  • [8] 6-ALKYL-2-METHOXY-4-(3H)-PYRIMIDINONES IN THE TRANSFORMATION OF PYRIMIDINES - REGIOSPECIFIC PREPARATION, ANTITUMOR AND ANTIMICROBIAL ACTIVITY OF 4-O-ACYLATED PYRIMIDINE-DERIVATIVES - NEW AGENTS FOR SELECTIVE ACYLATION OF AMINES
    BOTTA, M
    DEANGELIS, F
    NICOLETTI, R
    PANI, A
    MARONGIU, ME
    LACOLLA, P
    [J]. TETRAHEDRON LETTERS, 1988, 29 (22) : 2741 - 2744
  • [9] Structural modifications of benzanilide derivatives, effective potassium channel openers. X.
    Calderone, Vincenzo
    Coi, Alessio
    Fiamingo, Francesca Lidia
    Giorgi, Irene
    Leonardi, Michele
    Livi, Oreste
    Martelli, Alma
    Martinotti, Enrica
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2006, 41 (12) : 1421 - 1429
  • [10] A catalytic and tert-butoxide ion-mediated amidation of aldehydes with para-nitro azides
    Carbone, Giorgio
    Burnley, James
    Moses, John E.
    [J]. CHEMICAL COMMUNICATIONS, 2013, 49 (27) : 2759 - 2761